When was CNS Pharmaceuticals founded?

CNS Pharmaceuticals was founded in 2017 and raised its 1st funding round 9 years after it was founded.

Where is CNS Pharmaceuticals located?

CNS Pharmaceuticals is headquartered in Houston, United States.

Who is the current CEO of CNS Pharmaceuticals?

John Climaco of CNS Pharmaceuticals.

How many employees does CNS Pharmaceuticals have?

As of Aug 31, 2026, the latest employee count at CNS Pharmaceuticals is 13.

Is CNS Pharmaceuticals a funded company?

CNS Pharmaceuticals is a funded company, having raised a total of $***** in its 1st and only funding round, a Series B round on May 04, 2026.

When was the latest funding round of CNS Pharmaceuticals?

CNS Pharmaceuticals' latest funding was a $***** Series B round on May 04, 2026, with participation from 0 investor. Its primary sector is Oncology. In United States, the Oncology sector has seen $4.45B in funding in 2026 to date.

Where does CNS Pharmaceuticals rank among its competitors?

CNS Pharmaceuticals ranks 4th amongst 59 active competitors, of which 19 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Xintela, which secured $3.08M in Jun, 2026.

Who are the top competitors of CNS Pharmaceuticals?

CNS Pharmaceuticals' top competitors include Trogenix, Diakonos and Biodexa Pharmaceuticals. Among them, Xintela secured the most recent funding round in June, 2026.

CNS Pharmaceuticals - 2026 Company Profile, Team, Funding & Competitors

CNS Pharmaceuticals is a public company based in Houston (United States), founded in 2017. It operates as a Developer of treatments for primary and metastatic cancers in the brain and central nervous system. CNS Pharmaceuticals has raised $22.5M in funding. The company has 59 active competitors, including 19 funded and 8 that have exited. Its top competitors include companies like Trogenix, Diakonos and Biodexa Pharmaceuticals.

Company Details

Developer of treatments for primary and metastatic cancers in the brain and central nervous system. It offers a pipeline of anti-cancer drug candidates including berubicin that appears to cross the blood brain barrier and kill tumor cells and TPI 287 for glioblastoma multiforme.

Website: cnspharma.com
Social

Key Metrics

Founded Year

2017

Location

Houston, United States

Stage

Public

Total Funding

$22.5M in 1 round

Latest Funding Round

Series B, May 04, 2026, $*****

Investors

Falcon Capital

Ranked

4^th among 59 active competitors

Employee Count

13 as on Aug 31, 2026

Similar Companies

Trogenix & 57 more

Exit Details

Public

View CNS Pharmaceuticals' full profile

CNS Pharmaceuticals is associated with 4 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
CNS Pharmaceuticals, Inc. CIN: 0001729427 , United States, Active	Jul 27, 2017	-	4 (As on Dec 31, 2018)	-
CNS Pharmaceuticals Inc. CIN: 0798.108.179 , Belgium, Active	Feb 01, 2023	-	-	-
CNS PHARMACEUTICALS, INC. CIN: 32065885009 , United States, Active	Jan 09, 2018	-	-	-
CNS PHARMACEUTICALS, INC. CIN: 1729427 , United States, Active	Jun 18, 2007	-	5 (As on Dec 31, 2021)	-

CNS Pharmaceuticals got listed on Nov 08, 2019.

Click here to take a look at CNS Pharmaceuticals's IPO in detail

CNS Pharmaceuticals has raised a total funding of $22.5M over 1 round. CNS Pharmaceuticals has 1 institutional investor.

Here is the list of recent funding rounds of CNS Pharmaceuticals:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 04, 2026	6306872	Series B	5601808	6722685	2305491	6114630

Access funding benchmarks and valuations. Sign up today!

View details of CNS Pharmaceuticals's funding rounds and investors

CNS Pharmaceuticals' employee count trend

CNS Pharmaceuticals has 13 employees as of Aug 26. Here is CNS Pharmaceuticals's employee count trend over the years:

Employee count trend for CNS Pharmaceuticals

Uncover CNS Pharmaceuticals' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of CNS Pharmaceuticals include Trogenix, Diakonos and Biodexa Pharmaceuticals. Here is the list of Top 10 competitors of CNS Pharmaceuticals, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Trogenix 2023, Edinburgh (United Kingdom), Series A	Developer of precision cancer treatments using its proprietary gene therapy platform	$111M	IQ Capital, Ain & 9 others	60/100
2nd	Diakonos 2022, Houston (United States), Seed	Developer of dendritic cell vaccines for treating difficult cancer types	$31.4M	Restem, Buttonwood Titan QC Fund & 3 others	54/100
3rd	Biodexa Pharmaceuticals 2000, Cardiff (United Kingdom), Series A	Developer of therapeutics for the treatment of brain cancer	$6.79M	-	50/100
4th	CNS Pharmaceuticals 2017, Houston (United States), Public	Developer of treatments for primary and metastatic cancers in the brain and central nervous system	$22.5M	Falcon Capital	49/100
5th	NuvOx Therapeutics 2008, Tucson (United States), Funding Raised	Developer of an oxygen therapeutic drug designed to reverse tissue hypoxia	-	Pasadena Angels, Military Health & 1 others	49/100
6th	Xintela 2009, Lund (Sweden), Public	Stem-cell technology for cartilage damage and brain tumors	$931K	Smile Incubator, Flerie & 2 others	46/100
7th	OncoSynergy 2011, San Francisco (United States), Acquired	Developer of resistance mechanism inhibitors to treat cancer	$33.3M	Connecticut Innovations, National Cancer Institute ... & 4 others	43/100
8th	Modifi Bio 2021, New Haven (United States), Acquired	Developer of therapeutics for the treatment of cancer	$11.7M	BrightEdge, The Sontag Foundation & 6 others	42/100
9th	OVM 2012, Oxford (United Kingdom), Series B	Therapeutic peptide vaccines for cancer	$15.5M	Dxvx, Ukri & 13 others	41/100
10th	Systimmune 2014, Redmond (United States), Unfunded	Biopharmaceutical company developing innovative antibody-based therapies for cancer treatment	-	-	40/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on CNS Pharmaceuticals's competitors? Click here to see the top ones

CNS Pharmaceuticals has made no investments or acquisitions yet.

Here is the latest report on CNS Pharmaceuticals's sector:

Free

Oncology - Sector Report

Edition: August, 2026 (74 Pages)

View all reports related to CNS Pharmaceuticals

Media has covered CNS Pharmaceuticals for a total of 11 events in the last 1 year, 3 of them have been about company updates and 3 about people movement.